Northstar Advisory Group LLC Purchases Shares of 8,311 Pfizer Inc. (NYSE:PFE)

Northstar Advisory Group LLC bought a new stake in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 8,311 shares of the biopharmaceutical company’s stock, valued at approximately $233,000.

Several other large investors have also modified their holdings of the company. Naviter Wealth LLC boosted its position in Pfizer by 35.9% during the second quarter. Naviter Wealth LLC now owns 52,975 shares of the biopharmaceutical company’s stock worth $1,482,000 after purchasing an additional 13,988 shares in the last quarter. Magnus Financial Group LLC grew its position in Pfizer by 22.7% during the second quarter. Magnus Financial Group LLC now owns 38,756 shares of the biopharmaceutical company’s stock valued at $1,084,000 after acquiring an additional 7,169 shares during the period. Evermay Wealth Management LLC lifted its holdings in shares of Pfizer by 37.7% during the 2nd quarter. Evermay Wealth Management LLC now owns 20,592 shares of the biopharmaceutical company’s stock valued at $576,000 after acquiring an additional 5,636 shares in the last quarter. Capital Square LLC increased its stake in Pfizer by 4.0% during the 2nd quarter. Capital Square LLC now owns 12,414 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 473 shares during the period. Finally, Autumn Glory Partners LLC boosted its stake in Pfizer by 21.4% during the 2nd quarter. Autumn Glory Partners LLC now owns 13,375 shares of the biopharmaceutical company’s stock valued at $374,000 after acquiring an additional 2,355 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. UBS Group boosted their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Wells Fargo & Company lifted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Performance

PFE traded down $0.43 during midday trading on Tuesday, hitting $28.58. 18,128,736 shares of the company traded hands, compared to its average volume of 38,376,020. The company’s 50-day moving average is $29.01 and its 200 day moving average is $28.03. The firm has a market capitalization of $161.95 billion, a PE ratio of -477.33, a price-to-earnings-growth ratio of 1.02 and a beta of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $36.29. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the previous year, the company earned $0.67 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.88%. Pfizer’s payout ratio is currently -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.